Doha, Qatar: Sidra Medicine, a member of Qatar Foundation, has successfully conducted Qatar's first industry-sponsored pharmaceutical trial for pediatric congenital hyperinsulinism on a young patient.

Qatar Foundation member Sidra Medicine has conducted the industry-sponsored ‘sunRIZE’ trial for paediatric congenital hyperinsulinism. The first pharmaceutical trial comes after Sidra launched ...

This would be regarding the use of ersodetug in the ongoing phase 3 sunRIZE study targeting patients with Congenital Hyperinsulinism [cHI]. The reason investors should care about this trial before ...

Doha, Qatar: Sidra Medicine, a member of Qatar Foundation, has successfully conducted Qatar's first industry-sponsored pharmaceutical trial for pediatric congenital hyperinsulinism on a young patient.

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, ...

(Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced the U.